[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperactive-masseter-muscle\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperactive-masseter-muscle":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100613703",false,"NCT07270042","Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection","Evaluation of the Efficacy of Zinc on the Duration and Effictiveness of Botulinum Toxin A Injection in the Context of Hyperactive Masseter Muscle (A Prospective Clinical Study)","BTX-A","Inclusion Criteria:\n\nParticipants will be adults aged 18-60 years presenting with clinically confirmed masseteric hypertrophy or hyperactivity, as approved by EMG.\n\nExclusion Criteria:\n\n* Pregnancy or lactation;\n* Patients have aminoglycosides or vit B12.\n* Prior BTX-A treatment to the masseter within the previous 12 months;\n* Neuromuscular disorders or hypersensitivity to BTX-A or zinc compounds;\n* Systemic illness affecting zinc metabolism (e.g., hepatic, renal, or metabolic disorders);\n* Active infection, inflammation, or cutaneous lesions at the injection site.",true,"ALL","18 Years","60 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial seeks to investigate a promising new approach to enhance the effectiveness and duration of Botulinum Toxin A (BTX-A) for the treatment of hyperactive masseter muscles. By investigating the role of oral zinc supplementation, this study could provide a cost-effective, sustainable solution for patients suffering from both aesthetic concerns and functional limitations associated with MMH and bruxism. The findings of this study will expand the clinical applications of BTX-A, offering longer-lasting relief and reducing the need for frequent injections, which could revolutionize the management of MMH in clinical practice.",[28],"Hyperactive Masseter Muscle",[30,31,32,33],"Masseter Muscle","Botulinum Toxin","zinc","electromyographic (EMG)","NOT_YET_RECRUITING","2025-11-25",{"date":37,"type":38},"2025-12-08","ACTUAL",{"date":40,"type":22},"2025-12-01",{"date":42,"type":22},"2026-12-01",{"name":44,"class":45},"Tishreen University","OTHER",""]